Table 1 Baseline demographic and clinical characteristics by baseline-FPG and PPG-subgroup
Baseline FPG < 7 mmol/L (< 126 mg/dL) (controlled) | Baseline FPG ≥ 7 mmol/L (≥ 126 mg/dL) (uncontrolled) | |||||||
|---|---|---|---|---|---|---|---|---|
PPG respondersa Lixisenatide (n = 156) | PPG non-respondersb Lixisenatide (n = 127) | PPG respondersa Placebo (n = 47) | PPG non-respondersb Placebo (n = 210) | PPG respondersa Lixisenatide (n = 147) | PPG non-respondersb Lixisenatide (n = 157) | PPG respondersa Placebo (n = 23) | PPG non-respondersb Placebo (n = 204) | |
Female, n (%) | 88 (56.4) | 66 (52.0) | 18 (38.3) | 119 (56.7) | 72 (49.0) | 84 (53.5) | 9 (39.1) | 96 (47.0) |
Mean age, years (SD) | 58.1 (9.6) | 58.9 (9.6) | 56.0 (9.6) | 57.6 (9.8) | 55.5 (10.2) | 56.7 (10.0) | 56.7 (9.7) | 56.4 (10.1) |
Mean duration of diabetes, years (SD) | 12.6 (7.3) | 13.6 (7.1) | 9.0 (7.0) | 11.8 (7.3) | 10.5 (6.6) | 10.8 (6.5) | 11.7 (6.0) | 11.2 (6.8) |
Mean BMI, kg/m2 (SD) | 29.8 (6.3) | 30.9 (6.4) | 31.1 (6.8) | 29.4 (6.5) | 29.9 (6.3) | 31.1 (6.4) | 30.8 (5.9) | 29.8 (6.5) |
Mean HbA1c, mmol/mol (SD) | 62 (8.1) | 63 (8.3) | 57 (6.4) | 63 (8.1) | 67 (9.1) | 69 (9.6) | 66 (8.5) | 68 (9.0) |
Mean FPG, mmol/L (SD) | 5.50 (0.9) | 5.52 (0.9) | 5.57 (0.9) | 5.65 (0.9) | 8.94 (1.9) | 9.27 (2.0) | 9.23 (1.7) | 9.28 (1.8) |
Mean PPG, mmol/L (SD) | 14.08 (4.1) | 15.24 (3.9) | 11.58 (3.8) | 14.65 (4.2) | 16.21 (4.3) | 16.75 (4.4) | 14.09 (3.8) | 16.67 (4.2) |
Mean insulin dose. U (SD) | 42.4 (35.9) | 45.2 (24.4) | 40.3 (14.7) | 41.2 (24.9) | 41.9 (27.6) | 43.0 (24.1) | 53.0 (27.1) | 41.1 (29.0) |